681679-M

Iron Chelator IV, 21H7

The Iron Chelator IV, 21H7 controls the biological activity of iron-regulated enzymes. This small molecule/inhibitor is primarily used for Cancer applications.

• 同義詞: Iron Chelator IV, 21H7, 6-Bromo-Nʹ-(2-hydroxybenzylidene)-2-methylquinoline-4-carbohydrazide
• 經驗公式（希爾表示法）: C₁₈H₁₄BrN₃O₂
• 分子量：: 384.23
• 分類程式碼代碼: 12352200

屬性

• 品質等級: 100
• 化驗: ≥97% (HPLC)
• 形狀: solid
• 製造商／商標名: Calbiochem^®
• 儲存條件: OK to freeze; protect from light
• 顏色: off-white
• 溶解度: DMSO: 5 mg/mL, light yellow
• 儲存溫度: 2-8°C

描述

一般說明

A cell-permeable salicylaldehyde-acylhydrazone iron chelator that is 20-times more efficient than DFO/desferrioxamine (Cat. No. 252750) in depleting intracellular iron in colon cancer SW480 cells. Iron chelators exert their biological activities by affecting iron-regulated enzymes and singaling events, including HIF1α transcription activation (Effective [21H7] = 10 µM in SW480 and DLD-1 cells) due to inhibition of PHD- (prolyl hydroxylase) mediated HIF1α degradation, as well as stalling and enhancing, respectively, Ferritin and TfRI (Transferrin Receptor I) mRNA translation (Effective [21H7] = 10 µM in SW480 cells) due to iron depletion-induced IRP (Iron Regulatory Protein) IREs (Iron Response Elements) binding. Iron depletion is also reported to inhibit the growths of colorectal adenocarcinoma cultures, DLD-1 (IC₅₀ = 0.6 and 2.9 µM, respectively, by 21H7 and DFO) and SW480 (IC₅₀ = 1.0 and 3.8 µM, respectively, by 21H7 and DFO), as a result of Wnt signaling pathway blockage (Effective conc. = 5 µM 21H7 or 100 µM DFO).

警告

Toxicity: Standard Handling (A)

準備報告

Slight warming (45°C) is required for complete solubilization.

其他說明

Song, S., et al. 2011. Cancer Res.71, 7628.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable